(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/168300 A1

(51) International Patent Classification:
*C12N 5/0783* (2010.01) *A61K 35/17* (2015.01)
*C12N 5/10* (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2020/018443

(22) International Filing Date:
14 February 2020 (14.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 62/806,457 | 15 February 2019 (15.02.2019) | US |
| 62/841,066 | 30 April 2019 (30.04.2019) | US |
| 62/841,684 | 01 May 2019 (01.05.2019) | US |
| 62/943,649 | 04 December 2019 (04.12.2019) | US |


(71) Applicant: **EDITAS MEDICINE, INC.** [US/US]; 11 Hurley Street, Cambridge, MA 02141 (US).

(72) Inventors: **WELSTEAD, Gordon, Grant**; 12 Devon Terrace, Newton, MA 02459 (US). **BORGES, Christopher**; 21 Cumberland Rd., Reading, MA 01867 (US). **WONG, Karrie, Kawai**; 20 Warwick Street, Unit 3, Somerville, MA 02145 (US).

(74) Agent: **ZACHARAKIS, Maria, Laccotripe** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: MODIFIED NATURAL KILLER (NK) CELLS FOR IMMUNOTHERAPY

(57) Abstract: The present disclosure is directed to the generation of NK cells (or other lymphocytes) from induced pluripotent cells that have been derived from cells, e.g., developmentally mature T cells, and uses thereof for immunotherapy.

WO 2020/168300 A1